Search

Your search keyword '"Brentuximab Vedotin therapeutic use"' showing total 2 results
Start Over Descriptor "Brentuximab Vedotin therapeutic use" Region europe
2 results on '"Brentuximab Vedotin therapeutic use"'

1. [Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].

Author

Calleja A and Bouclet F

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Clinical Trials, Phase III as Topic, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Europe, Humans, Lymphoma, Large-Cell, Anaplastic pathology, Middle Aged, Multicenter Studies as Topic, Prednisone administration & dosage, Randomized Controlled Trials as Topic, Antineoplastic Agents, Immunological therapeutic use, Brentuximab Vedotin therapeutic use, Drug Approval, Lymphoma, Large-Cell, Anaplastic drug therapy
Published
2021
Full Text
View/download PDF

2. FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?

Author

Milunović V, Mišura Jakobac K, Kursar M, Mandac Rogulj I, and Ostojić Kolonić S

Subjects
Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Brentuximab Vedotin administration & dosage, Brentuximab Vedotin adverse effects, Clinical Trials, Phase III as Topic, Drug Approval, Europe, Hodgkin Disease diagnosis, Hodgkin Disease etiology, Humans, Multicenter Studies as Topic, Neoplasm Metastasis, Neoplasm Staging, Randomized Controlled Trials as Topic, Treatment Outcome, United States, United States Food and Drug Administration, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brentuximab Vedotin therapeutic use, Hodgkin Disease drug therapy
Abstract

ECHELON-1 study is a randomized open-labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow-up of 24.6 months, it has met its primary endpoint the reduction of modified progression-free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in-depth insight of pros and cons of this novel, promising but ultimately controversial regimen., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results